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Abstract
The synthesis of purine nucleotides has been studied in human peripheral blood lymphocytes from healthy subjects and
patients affected by B-cell chronic lymphocytic leukemia (B-CLL). The rate of the synthesis was measured by following the
incorporation of 14C-formate into the nucleotides of lymphocyte suspensions. The whole sequence AMPCADPCATP was
found reduced in B-CLL lymphocytes; in the case of guanylates only the last step of the sequence GMPCGDPCGTP was
significantly lower in the same cells. From the analysis of these results, combined with previous data, we conclude that purine
metabolism undergoes an imbalancement during CLL, which is partially compensated, and point out the importance of
studying concomitantly purine metabolism and nucleic acid synthesis in leukemia cells. ß 1999 Elsevier Science B.V. All
rights reserved.
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1. Introduction
In a previous paper, we studied the purine nucleo-
tide metabolism in lymphocytes of healthy subjects
and B-cell chronic lymphocytic leukemia patients [1].
We found a substantial decrease in absolute nucleo-
tide content, except for NAD and IMP. This de-
crease was less striking when values were expressed
per unit of proteins.
The activities of many enzymes of nucleotide me-
tabolism were investigated in lymphocytes from both
subjects: the enzymes involved in nucleotide catabo-
lism (AMP deaminase, purine nucleoside phospho-
rylase, adenosine deaminase), especially 5P-nucleo-
tidase, had reduced activities in leukemia patients.
As far as the two enzymes involved in the ‘salvage
pathway’ are concerned, hypoxanthine-guanine
phosphoribosyltransferase (HGPRT) was decreased,
and adenine phosphoribosyltransferase (APRT)
showed slightly increased activity. In preliminary ex-
periments, we also followed the incorporation of
14C-formate into IMP, total adenine nucleotides
and total guanine nucleotides. We found very low
labeling, especially in total adenylates of B-CLL lym-
phocytes, and we concluded that nucleotide synthesis
was impaired. All these changes indicate an imbal-
ance in purine metabolism in B-CLL; they are also
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potential markers of lymphoid malignancies and may
be useful in chemotherapy.
The intracellular nucleotide pool is synthesized by
interdependent metabolic processes: (1) ‘de novo
synthesis’ produces the purine ring from non-purine
precursors. It includes several steps and leads to the
formation of IMP from PRPP [2]; (2) ‘the inosinic
branch point’ is the section of the sequence where
IMP is channeled into AMP and GMP. AMP-succin-
ate synthetase is involved in the formation of AMP-
succinate, which is split into AMP+fumaric acid
by AMP-succinate lyase. IMP-dehydrogenase and
GMP-synthetase form ¢rst XMP and then ¢nally
GMP, from IMP; (3) the salvage pathway can read-
ily form mononucleotides from purine bases and
their nucleosides. Hypoxanthine-guanine phosphori-
bosyltransferase (HGPRT, EC 2.4.2.8) catalyzes the
formation of IMP from hypoxanthine and GMP
from guanine; this enzyme returns the major prod-
ucts of purine nucleotide catabolism to nucleotide
forms. Adenine phosphoribosyltransferase (APRT,
EC 2.4.2.7) catalyzes the conversion of adenine to
AMP, by a reaction similar to that of HGPRT: it
plays a minor role in purine salvage since adenine is
not a signi¢cant product of purine nucleotide catab-
olism [3]; and (4) di¡erent reactions produce nucleo-
side di- and triphosphates from AMP and GMP.
AMP is transformed into ADP by myokinase (EC
2.7.4.3):
ATPAMPHADP:
ATP may be formed from ADP, in several ways
(PRPP synthetase and its reverse; oxidative phos-
phorylation; substrate level phosphorylation). GMP
can be transformed into GDP and GTP by nucleo-
side monophosphate kinase (EC 2.7.4.8) and nucleo-
side diphosphate kinase (EC 2.7.4.6), respectively.
These phenomena are represented in Scheme 1.
It is evident that nucleoside mono-, di-, and tri-
phosphates are sequentially linked, and their forma-
tion is usually represented as a linear chain:
AMP! ADP! ATP
GMP! GDP! GTP:
Thus, we consider the synthesis of total adenylates
(A = AMP+ADP+ATP) and total guanylates
(G = GMP+GDP+GTP) cumulatively. This proce-
dure is acceptable, if we assume that AMP and
GMP mononucleotides are channeled as a constant
Scheme 1.
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£ux to ADP and GDP, ATP and GTP, which is a
reasonable assumption in normal conditions, but
must be veri¢ed in pathological situations.
In our previous experiments [1], we could not draw
any conclusion about the ‘inosinic branch point’, and
the subsequent transformations AMPCADPCATP
and GMPCGDPCGTP in leukemia cells. In the
present study, we followed the kinetic rate of incor-
poration of 14C-formate not only into IMP, but also
into AMP, GMP, ADP, GDP, ATP and GTP.
The aim of the present paper was to obtain more
information on the nucleotide biosynthesis in lym-
phocytes of B-CLL patients, with a particular inter-
est to the destiny of IMP at the inosinic branch
point, and to the linear chains AMPCATP and
GMPCGTP.
2. Materials and methods
2.1. Chemicals
The nucleotides used as chromatographic stand-
ards were obtained from Sigma (St. Louis, MO,
USA). The radiolabeled sodium-formate was ob-
tained from Amersham (Amersham, UK); Lympho-
prep was from Nycomed (Oslo, Norway). All other
chemicals were of analytical grade from Merck
(Darmstadt, Germany). All HPLC solvents were ¢l-
tered through 0.45-Wm membrane ¢lters (Sartorius,
Go«ttingen, Germany) prior to use.
2.2. lnstrumentation
For HPLC analysis, we used a Beckman chroma-
tograph equipped with two model 110 B pumps, a
model 166 UV detector set at 254 nm and a What-
man Partisil 10 SAX (4.6U250 mm) anion-exchange
column. Identi¢cation of nucleotides and their quan-
ti¢cation were carried out as previously described
[1,4,5].
2.3. Patients
Five normal subjects (age 48^65 years) and ¢ve
leukemia patients (60^75 years) were studied. The
patients had a mean history of B-CLL of 2.5 þ 0.5
years and attended the Hematological Division of
Siena University Hospital for monthly check-ups.
Diagnosis was performed on the basis of clinical
and hematological ¢ndings and cyto£uorimetric typ-
ing. At the time of blood sampling, the patients
had not undergone chemotherapy in the previous
2 months. Informed consent was obtained from the
healthy subjects and leukemia patients.
2.4. Preparation of total peripheral blood lymphocytes
(PBL)
All blood samples were drawn in the morning
(08.00 h) after overnight fasting; 60 ml of blood
from normal subjects was usually su⁄cient for the
determinations. In the leukemia patients, volumes
proportional to the counts were used. The lympho-
cytes were isolated from whole blood by density £oa-
tation [6]. FACS analysis did not reveal platelet con-
tamination. Lymphocytes, suspended in PBS to a
¢nal concentration of 10 000/Wl, were counted in a
Delcon cell counter. Cell viability was checked by
the Trypan blue exclusion test: the number of dead
cells was not signi¢cant.
2.5. Protein determination
Sonically treated lymphocyte extracts of each sam-
ple were prepared. Protein content of the extracts
was evaluated according to Bradford [7], using bo-
vine serum albumin as standard.
2.6. Kinetics of de novo synthesis of IMP and
synthesis of other nucleotides
We evaluated the kinetics of IMP and of other
nucleotides in the lymphocytes of healthy subjects
and B-CLL patients, according to the indications
of Gordon et al. [8]. After a pre-incubation period
of 30 min, 2 mM glutamine and 0.5 mM 14C-formate
(25 WCi/mol) were added to the incubation bu¡er
(pH 7.4) consisting of K2HPO4 (25 mmol/l), NaCl
(100 mmol/l), HEPES (20 mmol/l), glucose (5.5
mmol/l), glycine (4 mmol/l), NaHCO3 (10 mmol/l)
and bovine serum albumin (0.4%).
It is known that the rate of purine synthesis in
lymphocytes is dependent on a variety of factors,
the most signi¢cant being the concentration of phos-
phate. Henderson et al. [9] demonstrated that purine
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nucleotide synthesis in total leukocytes is stimulated
by increasing the concentration of phosphate in the
medium. The considerable increase probably re£ects
the availability of PRPP, the synthesis of which is
activated by phosphate [10]. The use of 25 mM phos-
phate in our experiments, according to Gordon [8]
has the advantage that the values of radioactivity
incorporation is larger than would be the case if
low phosphate concentrations were used: thus the
sensitivity and reliability of the measurements are
improved.
The lymphocytes were incubated for 17, 30, 60 and
154 min at a density of 6U106 cells/ml in an atmo-
sphere of 5% CO2 at 37‡C. At the above times,
6U106 cells were taken and washed twice with 2 ml
ice-cold PBS, then 100 Wl ice-cold 0.4 M HClO4 was
added to the cell pellet. All the details of the prepa-
ration of perchloric extracts and the criteria of deter-
mination of nucleotides by HPLC have been re-
ported in previous papers [1,4,5,9^12]. The peaks
(corresponding to AMP, ADP, ATP, GMP, GDP,
GTP and IMP) were collected directly in scintillation
vials and counted for radioactivity in Instagel scintil-
lant (added in 9/1 proportion to the collected frac-
tions) in a Packard 1500 Tri-Carb liquid scintillation
analyzer.
Since a gradient was used to resolve the nucleo-
tides, we checked the quenching of the radioactivity
at di¡erent bu¡er concentrations with standard sol-
utions of 14C-formate: no appreciable variations
were observed.
The results were expressed in pmol of 14C-formate
incorporated into the nucleotides, per 106 cells and
per mg of protein. The former is an absolute measure
and the latter a relative one [1].
2.7. Evaluation of the inosinic branch point
The inosinic branch point was evaluated through
the determination of radioactivity into IMP, AMP,
GMP, and the calculation of IMP/AMP and IMP/
GMP ratios. Low levels of these ratios are inversely
related to the channeling of IMP into adenine or
guanine mononucleotides, as shown in Scheme 1;
therefore, they indicate that the conversion of IMP
to AMP and GMP, respectively, is faster.
3. Results
In order to check the vitality of the cells during the
incubation time, in a preliminary experiment, we
evaluated the energy charge at the beginning and
end of the incubation period, both for healthy and
leukemia lymphocytes: it was 0.79 versus 0.77 in the
former and 0.72 versus 0.70 in the latter. The energy
charge was maintained, as previously reported [1].
Synthesis of IMP, AMP, ADP and ATP was lower
in leukemia cells than in healthy lymphocytes. Fig. 1
shows IMP synthesis in lymphocytes of healthy sub-
Fig. 1. Incorporation of 14C-formate into IMP of PBL from
healthy subjects and leukemia patients at di¡erent incubation
times (see Section 2.6). The results are expressed in pmol of
14C-formate incorporated into the nucleotides of 106 cells and
into the nucleotides referred to 1 mg of protein. Bars indicate
standard deviation.
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jects and leukemia patients, expressed in pmol of
14C-formate/106 cells and pmol/mg protein. Figs. 2
and 3 show synthesis of AMP, ADP, ATP.
The incorporation of 14C-formate by GMP and
GDP was not signi¢cantly di¡erent in lymphocytes
from the two groups of subjects, but was lower for
GTP, in the leukemia cells, when values were ex-
pressed in pmol/106 cells (Fig. 4). When results
were expressed/mg protein, incorporation by GMP
and GDP did not show signi¢cant variations in the
leukemia cells, but was lower for GTP (Fig. 5).
The IMP/AMP and IMP/GMP ratios were calcu-
lated from the 14C-formate incorporated into the nu-
Fig. 2. Incorporation of 14C-formate into adenine nucleotide of
PBL from healthy subjects and leukemia patients at di¡erent in-
cubation times (see Section 2.6). The results are expressed in
pmol of 14C-formate incorporated into the nucleotides of 106
cells. Bars indicate standard deviation.
Fig. 3. Incorporation of 14C-formate into adenine nucleotide of
PBL from healthy subjects and leukemia patients at di¡erent in-
cubation times (see Section 2.6). The results are expressed in
pmol of 14C-formate incorporated into the nucleotides and are
referred to 1 mg of protein. Bars indicate standard deviation.
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cleotides of 106 cells (Table 1). The IMP/AMP ratio
was lower in leukemia cells (1.09 versus 3.10 at 154
min); even higher was the decrease of the IMP/GMP
ratio (1.51 versus 7.90 at 154 min).
The protein content shifted from an average of
36.40 þ 3.2 Wg/106 cells to 21.00 þ 1.9 Wg/106 cells in
B-CLL lymphocytes (means þ S.E.).
4. Discussion
Some results of our present study deserve attentive
scrutiny.
(1) The ‘de novo’ synthesis of IMP which occurs
through the well-known PRPPCIMP sequence, with
two points of 14C-formate uptake, was found to be
impaired in leukemia cells, both in absolute and rel-
ative terms. Ten reactions are involved in the trans-
formation of PRPP into IMP. The reactions in which
14C-formate is taken up by the precursors of IMP
molecule are: (a) 5P-phosphoribosylglycinamideC
5P-phosphoribosyl-N-formylglycinamide; and (b) 5P-
phosphoribosyl-4-carboxamide-5P-aminoimidazoleC
5P-phosphoribosyl-4-carboxamide-5P-formamidoimid-
azole.
An interesting future task will be to ascertain
which enzymes have lower activity in lymphocytic
leukemia.
(2) At the ‘inosinic branch point’, AMP incorpo-
rated less 14C-formate, however the results were ex-
pressed. In the case of GMP, no substantial di¡er-
ence was observed when the results were expressed
per 106 cells; the variations expressed per mg protein
were not signi¢cant.
A great deal of information can be deduced from
the IMP/AMP and IMP/GMP ratios. These param-
eters, especially the latter, were depressed in leukemia
cells. This means that even if the rate of IMP, AMP
and GMP formation is lower in leukemia cells, as
indicated by 14C-formate incorporation, the channel-
ing of IMP into AMP or GMP, at the ‘inosinic
Fig. 4. Incorporation of 14C-formate into guanine nucleotide of
PBL from healthy subjects and leukemia patients at di¡erent in-
cubation times (see Section 2.6). The results are expressed in
pmol of 14C-formate incorporated into the nucleotides of 106
cells. Bars indicate standard deviation.
Table 1
Nucleotide ratios
17 min 30 min 60 min 154 min
IMP/AMP
Healthy subjects 0.44 1.20 1.26 3.10
Leukemia patients 0.53 0.66 1.20 1.09
IMP/GMP
Healthy subjects 1.82 3.39 6.82 7.90
Leukemia patients 1.34 0.74 1.12 1.51
The ratios were calculated from the mean values of 14C-formate
incorporation into nucleotides.
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branch point’, is relatively faster than in normal cells,
especially for GMP. This phenomenon may compen-
sate the lower synthesis of IMP, to ensure a satisfac-
tory formation of nucleotides.
(3) On the basis of incorporation data, the entire
sequence AMPCADPCATP is reduced in B-CLL
lymphocytes, both when results are expressed per 106
cells and per mg protein.
The situation is partially di¡erent for guanylates.
Only the last step of the sequence GMPC
GDPCGTP is signi¢cantly lower in leukemia cells,
as shown by the fact that GTP content (which is
normally the most abundant of the guanine nucleo-
tides) is the most depressed in leukemia cells [1], as
well as its labeling after 14C-formate, as shown by
our present data.
(4) The present results are consistent with the pre-
viously reported analysis of nucleotide content in
leukemia cells [1], in which all compounds were
found to be lower. Di- and triphosphates were re-
duced in leukemia cells (ATP by 55% and GTP
by 70%, when referred to 106 cells) ; the reduction
was less evident if the data was expressed per mg
protein.
(5) In the previous paper [1], we underlined the
lower activity of all enzymes involved in nucleotide
catabolism, the low and not signi¢cant increase in
APRT and the 30% decrease in HGPRT, and we
tried to understand the reduction in nucleotide con-
tent observed in leukemia cells.
Combining such results with the present data, we
conclude that the decrease of the nucleotide content
in leukemia cells seems to be only partially compen-
sated, and we can better interpret such variations on
enzymatic and kinetic basis.
(6) According to our precedent results [1], only
IMP increased. The present research excludes that
the IMP accumulation is linked to reduced channel-
ing at the inosinic branch point, but is more prob-
ably due to the lower activity of IMPase [1].
The absolute levels of AMP, ADP and ATP,
whenever they are referred to 106 cells or to proteins,
are reduced [1]. The channeling of IMP towards
AMP and total adenylates is relatively accelerated,
as shown by the decrease of IMP/AMP ratio, but
not enough to restore the normal values of adenine
nucleotides.
The behavior of guanylates requires a speci¢c
comment. The levels of GMP, GDP and GTP, are
lower in leukemia cells [1], with the GTPs
GDPsGMP order. This is in agreement with the
fact that we did not observe signi¢cant a di¡erence
between labeling of GMP and GDP, in the two
Fig. 5. Incorporation of 14C-formate into guanine nucleotide of
PBL from healthy subjects and leukemia patients at di¡erent in-
cubation times (see Section 2.6). The results are expressed in
pmol of 14C-formate incorporated into the nucleotides and are
referred to 1 mg of protein. Bars indicate standard deviation.
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groups of subjects, and only a very low radioactivity
in GTP in leukemia cells.
As shown by the values of IMP/GMP ratio, at the
‘inosinic branch point’, the channeling of IMP to-
wards GMP and total guanylates is preferentially
increased, even if only in relative terms. It is likely
that this is not due to an enhanced number of en-
zyme molecules involved (IMP dehydrogenase and
GMP synthetase), but to a reduced feed-back inhib-
ition by the guanylates. However, the normal values
are not restored, since the activity of HGPRT is
impaired [1].
Bearing in mind all these data, the reduced nucleic
acid synthesis [1] and the lower protein synthesis
(which is GTP-dependent) demonstrated by the low
protein content of leukemia cells, one may conclude
that the reduced guanylate levels are due to a de-
creased synthesis, in absolute terms, and not to an
increased utilization: the di¡erent behavior of GDP
and GTP, can be better explained if we consider that
they are formed by two di¡erent enzymes, the nu-
cleoside monophosphate kinase (EC 2.7.4.8) and the
nucleoside diphosphate kinase (EC 2.7.4.6), respec-
tively.
Our research con¢rms the conclusion that it is al-
ways very important to understand the degree at
which purine metabolism is impaired in leukemia
cells and how this is re£ected in nucleic acid synthe-
sis. The enzymes involved in de novo synthesis, nu-
cleotide catabolism and salvage pathway, their activ-
ity and structure, the corresponding genes, their
regulation at metabolic and genomic level, deserve
further consideration, for a better understanding of
the life span of leukemia cells and of their viability:
they may represent markers for precocious diagnosis,
familiarity studies, for monitoring the disease; ¢-
nally, they may represent the target for a rational
chemotherapy.
The importance of guanylates must be speci¢cally
underlined. GTP controls the protein synthesis; the
A/G ratio regulates the synthesis of nucleic acids;
both phenomena are of extraordinary importance
in the biology of the leukemia cells [4,13^15]. As
shown by our experiments, guanylate metabolism
seems to be speci¢cally impaired in leukemia cells:
there is a relatively increased channeling of IMP to-
wards GMP; HGPRT and nucleoside di-phosphate
kinase deserve further study, in order to understand
the signi¢cance of their changes and the importance
in the pathogenesis of leukemia.
The present research con¢rms the conclusion
reached in our precedent paper [1], where we under-
lined the importance of studying concomitantly pu-
rine metabolism and its relationship with nucleic acid
synthesis in leukemia cells.
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